What is the appropriate management for a patient with hematemesis after recent coronary artery bypass graft (CABG) surgery?

Management of Hematemesis Post-CABG

In a patient with hematemesis after recent CABG, immediately discontinue all antiplatelet and anticoagulant therapy, initiate IV proton pump inhibitor therapy, perform urgent upper GI endoscopy (ideally within 12 hours), and restart aspirin alone within 24-48 hours once hemostasis is achieved—continuing aspirin if possible even during active bleeding to prevent catastrophic stent or graft thrombosis.

Immediate Management Algorithm

Step 1: Hemodynamic Stabilization

• Establish IV access and begin aggressive fluid resuscitation
• Transfuse red blood cells only if hemoglobin drops below 80 g/L or hematocrit below 25% 1
• Avoid excessive transfusion as it may worsen outcomes
• Monitor for signs of hypovolemic shock (tachycardia, hypotension)

Step 2: Antiplatelet/Anticoagulant Management - Critical Decision Point

This is where the evidence becomes nuanced and requires careful judgment:

If the patient is on dual antiplatelet therapy (DAPT):

• Discontinue the P2Y12 inhibitor immediately (clopidogrel, ticagrelor, or prasugrel) 2
• Continue aspirin if at all possible, even during active bleeding 2, 3
• The rationale: A case report demonstrated that stopping both antiplatelet agents led to stent thrombosis within 39 hours, resulting in ventricular tachycardia and RCA occlusion 2

If bleeding is truly life-threatening:

• You may need to stop both agents temporarily
• However, understand this creates extreme thrombotic risk
• Plan to restart aspirin within 24 hours of achieving hemostasis 3
• Restart P2Y12 inhibitor within 5 days maximum to prevent stent/graft thrombosis 3

Step 3: Pharmacologic Interventions

• Start IV proton pump inhibitor immediately - high-dose continuous infusion 1
• Consider octreotide if variceal bleeding suspected
• Reverse anticoagulation if present:
  • For warfarin: Give Octaplex (prothrombin complex concentrate) if INR elevated 1
  • For heparin/enoxaparin: Consider protamine 1
  • Recombinant Factor VII only for severe, life-threatening bleeding 1

Step 4: Urgent Endoscopy

• Perform upper GI endoscopy within 12 hours (ideally sooner if hemodynamically unstable) 2
• 82% of post-CABG GI bleeds originate from duodenal ulceration 4
• Other sources: gastric ulcers (10%), Mallory-Weiss tears (2%), esophagitis 4
• Endoscopy is safe in post-CABG patients with no reported complications in studies 4
• Endoscopic hemostasis should be achieved to allow earlier reinitiation of antiplatelet therapy 2

Risk Factors Present in This Patient

Post-CABG patients who develop GI bleeding typically have:

• Older age (mean 65.6 years vs 58.7 in controls) 4
• Inotropic support requirement post-operatively 4
• History of peptic ulcer disease (38% vs 9% in controls) 4
• Lack of perioperative H2-blocker/PPI prophylaxis (4% vs 20% in controls) 4

Critical Pitfall: The Thrombosis-Bleeding Balance

The most dangerous error is completely stopping all antiplatelet therapy. The evidence is stark:

• Discontinuing aspirin in patients on secondary prevention increases major adverse cardiac events by 3-fold 3
• In patients with coronary stents, the odds ratio for major cardiac events jumps to 89 when aspirin is stopped 3
• One study showed stopping antithrombotic therapy increased thrombotic event risk (HR 5.77) and mortality (HR 3.32) 3

The key principle: Maintain aspirin if humanly possible, sacrifice only the P2Y12 inhibitor temporarily.

Timing of Antiplatelet Reinitiation

Once endoscopic hemostasis is achieved:

1. Aspirin: Restart within 24 hours if stopped 3
2. P2Y12 inhibitor: Must restart within 5 days maximum due to high stent/graft thrombosis risk after this timeframe 3
3. This 5-day window represents the optimal balance between rebleeding and thrombosis risk 3

Consultation Requirements

• Immediate cardiothoracic surgery consultation - they performed the CABG and need to be involved 5
• Interventional cardiology consultation if patient has coronary stents 2, 3
• Gastroenterology for urgent endoscopy 2

Long-term Considerations

• Post-CABG GI bleeding carries 20% surgical intervention rate if endoscopic therapy fails 4
• Mortality from the bleeding itself is low if managed appropriately 4
• However, the thrombotic complications from stopping antiplatelet therapy can be catastrophic 2, 3
• Restart PPI prophylaxis for duration of antiplatelet therapy 6

Special Circumstances

If patient required re-exploration for bleeding post-CABG:

• These patients have higher 12-hour blood loss volumes
• Associated with inferior long-term survival 7
• More aggressive monitoring and earlier endoscopy warranted

If CABG was performed <5 days after stopping P2Y12 inhibitor:

• Patient already at higher bleeding risk 8
• May explain the GI hemorrhage
• Still must balance against thrombotic risk when managing current bleed